RESUMEN
Ondansetron HCl is a (5-HT3) serotonin receptor antagonist, used as anti-emetic drug in combination with anticancer agents. Conventional dosage forms have poor bioavailability and patient compliance. These problems can be reduced by the use of nasal niosomal thermo-reversible in situ gelling system. Niosomes were formulated using various surfactants (Span 60, Span 80, Tween 20, and Tween 80) in different ratios using the thin-film hydration technique. Niosomes were evaluated for particle size, zeta potential, transmission electron microscopy (TEM) imaging, drug entrapment efficiency, and in vitro drug release. Niosomes prepared using Span 60 and cholesterol in the ratio 1:1 (F5) showed higher entrapment efficiency (76.13 ± 1.2%) and in vitro drug release (91.76%) after 12 h was optimized. The optimized niosomes were developed into thermo-reversible in situ gel, composed of Poloxamer 407 and sodium carboxymethyl cellulose, prepared by cold method technique. Compatibility study (FTIR, DSC) was made for drugs and excipients that showed no significant interaction. The gel formulation G5 showed the most suitable gelation temperature (31 °C), viscosity (1250 mpoise), bioadhesion force (5860 ± 28 dyne/cm2), and in vitro drug release (70.6%) after 12 h. Comparative in vivo pharmacokinetic study on rabbits showed a sustained release and higher relative bioavailability of the prepared nasal in situ gel compared to similar dose of oral tablets (202.4%) which make ondansetron HCl niosomal nasal thermo-sensitive in situ gel a more convenient dosage form for the administration of ondansetron HCl than oral tablets.
Asunto(s)
Composición de Medicamentos/métodos , Sistemas de Liberación de Medicamentos/métodos , Mucosa Nasal/efectos de los fármacos , Ondansetrón/administración & dosificación , Ondansetrón/síntesis química , Administración Intranasal/métodos , Animales , Antieméticos/administración & dosificación , Antieméticos/síntesis química , Antieméticos/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Liberación de Fármacos/efectos de los fármacos , Liberación de Fármacos/fisiología , Liposomas , Masculino , Mucosa Nasal/metabolismo , Ondansetrón/metabolismo , ConejosRESUMEN
A mechanism that enables direct aldehyde C-H functionalization has been achieved via the synergistic merger of photoredox, nickel, and hydrogen atom transfer catalysis. This mild, operationally simple protocol transforms a wide variety of commercially available aldehydes, along with aryl or alkyl bromides, into the corresponding ketones in excellent yield. This C-H abstraction coupling technology has been successfully applied to the expedient synthesis of the medicinal agent haloperidol.
Asunto(s)
Aldehídos/química , Antieméticos/síntesis química , Haloperidol/síntesis química , Hidrocarburos Aromáticos/química , Hidrógeno/química , Níquel/química , Aldehídos/síntesis química , Alquilación , Antieméticos/química , Bromuros/síntesis química , Bromuros/química , Catálisis , Haloperidol/química , Hidrocarburos Aromáticos/síntesis química , Oxidación-Reducción , Procesos FotoquímicosRESUMEN
As autoras analisam as aplicações da bromoprida em Pediatria, atualizando dados sobre sua farmacocinética, farmacodinâmica, as possíveis reações colaterais decorrentes de seu uso, bem como as principais indicações e respectiva posologia, complementando o trabalho com extensa relação de referências bibliográficas.
Asunto(s)
Humanos , Masculino , Femenino , Niño , Adulto , Antieméticos/farmacocinética , Antieméticos/síntesis química , Antieméticos/uso terapéuticoRESUMEN
Chemotherapy can be a life-prolonging treatment for many cancer patients, but it is often associated with profound nausea and vomiting that is so distressing that patients may delay or decline treatment to avoid these side effects. EMEND (aprepitant) is the first and only neurokinin-1 (NK-1) receptor antagonist available on the market for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Aprepitant acts centrally at NK-1 receptors in vomiting centers within the central nervous system to block their activation by substance P released as an unwanted consequence of chemotherapy. By controlling nausea and vomiting, EMEND helps improve patients' daily living and their ability to complete multiple cycles of chemotherapy. The development of aprepitant included a novel nanoparticle formulation to optimize oral absorption and innovative chemistry to discover a prodrug form suitable for intravenous administration to improve compliance and convenience for healthcare professionals and cancer patients.
Asunto(s)
Morfolinas/síntesis química , Morfolinas/uso terapéutico , Náusea/prevención & control , Vómitos/prevención & control , Antieméticos/síntesis química , Antieméticos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Aprepitant , Descubrimiento de Drogas/historia , Descubrimiento de Drogas/tendencias , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Modelos Biológicos , Náusea/inducido químicamente , Neoplasias/tratamiento farmacológico , Antagonistas del Receptor de Neuroquinina-1 , Vómitos/inducido químicamenteRESUMEN
The aim of this study was to optimize and formulate fast disintegrating tablets (FDTs) for nausea and vomiting using aminoacetic acid, carmellose and sodium alginate with enough mechanical strength. Ondansetron HCl (water soluble) or domperidone (water insoluble) drug were added to FDTs and their disintegration behaviour was evaluated. Plackett Burman Screening Design was used to screen the independent active process variables [concentration of aminoacetic acid (X (1)), concentration of carmellose (X (2)) and tablet crushing strength (X (3))] which were found to actively influence the dependent variables [disintegration time in the mouth (DT), wetting time (WT), and water absorption ratio (WAR)] for both the drugs. Also, the coefficients of active variables (DT, WT and WAR) of FDTs containing domperidone was found to be significantly different (P < 0.05) from the coefficients of active factors (X (1), X (2) and X (3)) containing ondansetron HCl FDTs. Further, FDTs containing domperidone was prepared according to central composite design for estimating the effect of active factors (X (1), X (2), X (3)) in extended spherical domain. The regression analysis of quadratic fit revealed that DT, WT and WAR were 98% correlated with active factors (X (1), X (2) or X (3)). The optimized domperidone FDTs were further compared with superdisintegrants (croscarmellose sodium or crospovidone). The data revealed that optimized domperidone FDTs were better than domperidone FDTs containing croscarmellose or crospovidone. Hence, this novel excipients combination can be used for delivery of water insoluble drugs in place of superdisintegrants.
Asunto(s)
Química Farmacéutica/métodos , Náusea/tratamiento farmacológico , Comprimidos/síntesis química , Vómitos/tratamiento farmacológico , Adolescente , Adulto , Antieméticos/administración & dosificación , Antieméticos/síntesis química , Antieméticos/farmacocinética , Femenino , Humanos , Masculino , Boca/efectos de los fármacos , Boca/metabolismo , Náusea/metabolismo , Solubilidad/efectos de los fármacos , Comprimidos/administración & dosificación , Comprimidos/farmacocinética , Factores de Tiempo , Vómitos/metabolismo , Adulto JovenRESUMEN
Sila-substitution of drugs (the carbon/silicon switch) is a concept that is being successfully used for the development of new chemical entities. The (R)-sila-analogue of the antidepressant venlafaxine is devoid of the serotonin reuptake inhibition observed with the marketed drug, leading to a selective noradrenaline reuptake inhibitor displaying anti-emetic properties.
Asunto(s)
Antieméticos/farmacología , Antieméticos/uso terapéutico , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Vómitos/tratamiento farmacológico , Animales , Antieméticos/síntesis química , Cristalografía por Rayos X , Ciclohexanoles/química , Ciclohexanoles/farmacología , Ciclohexanoles/uso terapéutico , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Hurones , Humanos , Técnicas In Vitro , Masculino , Modelos Moleculares , Estructura Molecular , Antagonistas del Receptor de Serotonina 5-HT3 , Inhibidores Selectivos de la Recaptación de Serotonina/síntesis química , Estereoisomerismo , Relación Estructura-Actividad , Clorhidrato de VenlafaxinaRESUMEN
A series of 4,4-disubstituted cyclohexylamine NK(1) antagonists containing a lactam ring is described. The compounds are brain penetrant and activity is demonstrated in a ferret emesis model.
Asunto(s)
Antieméticos/síntesis química , Antieméticos/farmacología , Lactamas/química , Lactamas/farmacología , Taquicininas/antagonistas & inhibidores , Amidas/química , Animales , Antieméticos/química , Gerbillinae , Humanos , Concentración 50 Inhibidora , Lactamas/síntesis química , Metilación , Estructura Molecular , Receptores de Neuroquinina-1/metabolismo , Relación Estructura-Actividad , Taquicininas/metabolismoRESUMEN
A structurally original series of N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides derived from the corresponding benzamide 5 were prepared and evaluated for their binding affinity for the dopamine D(2) and serotonin 5-HT(3) receptors using rat striatum and rat cortical membrane, respectively. Many of the synthesized pyridine-3-carboxamides exhibited nanomolar binding affinity for the serotonin 5-HT(3) receptor along with moderate to high binding affinity for the dopamine D(2) receptor. Introduction of the more lipophilic bromine atom and methylamino group at the 5- and 6-positions of the pyridine ring, respectively, enhanced the affinity for the dopamine D(2) receptor while keeping a potent serotonin 5-HT(3) receptor binding affinity. As a result of structure-affinity relationships, the 5-bromo-2-methoxy-6-methylaminopyridine-3-carboxamide 53 was selected as the most promising product showing a high binding affinity for both receptors. Compound 53 affinity for the dopamine D(2) and serotonin 5-HT(3) receptors was much more potent than that of metoclopramide (dopamine D(2) receptor; 23.3 nM vs 444 nM, serotonin 5-HT(3) receptor; 0.97 nM vs 228 nM). Optical resolution of the racemate 53 brought about a dramatic change in the pharmacological profile with (R)-53 exhibiting a strong affinity for both the dopamine D(2) and serotonin 5-HT(3) receptors, while the corresponding (S)-53 had a potent serotonin 5-HT(3) receptor binding affinity and a moderate dopamine D(2) receptor binding affinity. X-ray crystallographic study of (R)-53 revealed the existence of two energically stable conformers just like two mirror images. This may account for (R)-53 high affinity for both the dopamine D(2) and serotonin 5-HT(3) receptors. Pharmacologically, (R)-53 [AS-8112] showed a potent antagonistic activity for both the dopamine D(2) and serotonin 5-HT(3) receptors in vivo tests and dose-dependently inhibited both the incidence and frequency of emetic episodes induced by cisplatin (ferrets) and morphine (dogs) with ID(50) values of 27.1 microg/kg, po and 136 microg/kg, po, respectively. On the basis of this pharmacological profile, (R)-53 is now under further investigation as a potential broad antiemetic agent.
Asunto(s)
Antieméticos/síntesis química , Azepinas/síntesis química , Antagonistas de Dopamina/síntesis química , Piridinas/síntesis química , Receptores de Dopamina D2/efectos de los fármacos , Receptores de Serotonina/efectos de los fármacos , Antagonistas de la Serotonina/síntesis química , Animales , Antieméticos/química , Antieméticos/farmacología , Azepinas/química , Azepinas/farmacología , Encéfalo/metabolismo , Cristalografía por Rayos X , Perros , Antagonistas de Dopamina/química , Antagonistas de Dopamina/farmacología , Hurones , Técnicas In Vitro , Modelos Moleculares , Piridinas/química , Piridinas/farmacología , Ratas , Receptores de Dopamina D2/metabolismo , Receptores de Serotonina/metabolismo , Receptores de Serotonina 5-HT3 , Antagonistas de la Serotonina/química , Antagonistas de la Serotonina/farmacología , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
A series of novel spiroether-based neurokinin-1 (NK(1)) antagonists is described. The effect of modifications to the spiroether ring and aromatic substituents are discussed, leading to the identification of compounds with high affinity and excellent CNS penetration.
Asunto(s)
Éteres/síntesis química , Éteres/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Compuestos de Espiro/síntesis química , Compuestos de Espiro/farmacología , Animales , Antieméticos/síntesis química , Antieméticos/farmacología , Conducta Animal/efectos de los fármacos , Unión Competitiva/efectos de los fármacos , Células CHO , Cricetinae , Perros , Hurones , Gerbillinae , Humanos , RatasRESUMEN
In search of a dopamine D2 and serotonin 5-HT3 receptors dual antagonist as a potential broad antiemetic agent, a number of benzamides were prepared from 4-amino-5-chloro-2-methoxybenzoic acid derivatives and 6-amino-1,4-dialkylhexahydro-1,4-diazepines and evaluated for their binding affinity for the dopamine D2 and the serotonin 5-HT3 receptors using rat brain synaptic and rat cortical membranes, respectively. From the results of both in vitro receptor binding and in vivo biological assays for the dopamine D2 receptor, 1-ethyl-4-methylhexahydro-1,4-diazepine ring was selected as an optimum amine moiety. Introduction of one methyl group on the nitrogen atom at the 4-position and/or modification of the substituent at the 5-position of the 4-amino-5-chloro-2-methoxybenzoyl moiety caused a marked increase in the dopamine D2 receptor binding affinity along with a potent 5-HT3 receptor binding affinity. Among the compounds, 5-chloro-N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)-2-methoxy-4-methylaminobenzamide (82), 5-bromo (110), and 5-iodo (112) analogues exhibited a much higher affinity for the dopamine D2 receptor than that of metoclopramide (IC50=17.5-61.0 nM vs. 483 nM). In particular, 82 showed a potent antagonistic activity for both receptors in vivo tests. Optical resolution of the racemate 82 brought about a dramatic change in the pharmacological profile with the (R)-enantiomer exhibiting a strong affinity for both the dopamine D2 and the 5-HT3 receptors, while the corresponding (S)-enantiomer had a potent and selective serotonin 5-HT3 receptor binding affinity.
Asunto(s)
Antieméticos/síntesis química , Antieméticos/farmacología , Benzamidas/síntesis química , Benzamidas/farmacología , Antagonistas de Dopamina/síntesis química , Antagonistas de Dopamina/farmacología , Antagonistas de los Receptores de Dopamina D2 , Receptores de Serotonina/efectos de los fármacos , Antagonistas de la Serotonina/síntesis química , Antagonistas de la Serotonina/farmacología , Animales , Apomorfina/antagonistas & inhibidores , Apomorfina/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Fenómenos Químicos , Química Física , Cromatografía Líquida de Alta Presión , Perros , Eméticos/antagonistas & inhibidores , Eméticos/farmacología , Técnicas In Vitro , Indicadores y Reactivos , Ratas , Receptores de Serotonina 5-HT3 , Relación Estructura-ActividadRESUMEN
1-(5-[[(2R,3S)-2-([(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethyl]oxy)-3-(4-fluorophenyl)morpholin-4-yl]methyl]-2H-1,2,3-triazol-4-yl)-N,N-dimethylmethanamine hydrochloride 3 is a high affinity, orally active, h-NK(1) receptor antagonist with a long central duration of action and a solubility in water of >100 mg/mL. The construction of the 5-dimethylaminomethyl 1,2,3-triazol-4-yl unit, which incorporates the solubilizing group of 3, was accomplished by thermal rearrangement of a propargylic azide in the presence of dimethylamine. Compound 3 is highly effective in pre-clinical tests that are relevant to clinical efficacy in emesis and depression.
Asunto(s)
Antidepresivos/síntesis química , Antieméticos/síntesis química , Morfolinas/síntesis química , Antagonistas del Receptor de Neuroquinina-1 , Triazoles/síntesis química , Administración Oral , Aminas/síntesis química , Aminas/química , Aminas/farmacología , Animales , Animales Recién Nacidos , Antidepresivos/química , Antidepresivos/farmacología , Antieméticos/química , Antieméticos/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Perros , Hurones , Gerbillinae , Cobayas , Técnicas In Vitro , Inyecciones Intravenosas , Macaca mulatta , Morfolinas/química , Morfolinas/farmacología , Ensayo de Unión Radioligante , Ratas , Solubilidad , Relación Estructura-Actividad , Triazoles/química , Triazoles/farmacología , Vocalización Animal/efectos de los fármacosRESUMEN
An effective and practical synthetic route to methyl 2-methoxy-6-methylaminopyridine-3-carboxylate (7), the key intermediate of 5-bromo-2-methoxy-6-methylaminopyridine-3-carboxylic acid (1), from 2,6-dichloro-3-trifluoromethylpyridine (12) was undertaken. Process improvements were highlighted by regioselectivity of 12 with a nitrogen nucleophile and conversion of the 3-trifluoromethyl group into the methoxycarbonyl group. The reaction of 12 with N-benzylmethylamine provided the 6-(N-benzyl-N-methyl)aminopyridine 26a and the regioisomer 26b in >98:<2 ratio in a quantitative yield. Treatment of 2-methoxy-6-methylamino-3-trifluoropyridine (14a) with a large excess of sodium methoxide followed by acid hydrolysis gave the pyridine-3-carboxylic ester 7 in an excellent yield. The potential application of this reaction is also described.
Asunto(s)
Antieméticos/síntesis química , Azepinas/síntesis química , Ácidos Nicotínicos/síntesis química , Piridinas/química , Piridinas/síntesis química , Cromatografía Líquida de Alta Presión , Indicadores y Reactivos , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Espectrometría de Masa Bombardeada por Átomos Veloces , Espectrofotometría InfrarrojaRESUMEN
The regioselective dibenzylphosphorylation of 2 followed by catalytic reduction in the presence of N-methyl-D-glucamine afforded 2-(S)-(1-(R)-(3, 5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(5-(2- phosphoryl-3-oxo-4H,-1,2,4-triazolo)methylmorpholine, bis(N-methyl-D-glucamine) salt, 11. Incubation of 11 in rat, dog, and human plasma and in human hepatic subcellular fractions in vitro indicated that conversion to 2 would be expected to occur in vivo most readily in humans during hepatic circulation. Conversion of 11 to 2 occurred rapidly in vivo in the rat and dog with the levels of 11 being undetectable within 5 min after 1 and 8 mg/kg doses iv in the rat and within 15 min after 0.5, 2, and 32 mg/kg doses iv in the dog. Compound 11 has a 10-fold lower affinity for the human NK-1 receptor as compared to 2, but it is functionally equivalent to 2 in preclinical models of NK-1-mediated inflammation in the guinea pig and cisplatin-induced emesis in the ferret, indicating that 11 acts as a prodrug of 2. Based in part on these data, 11 was identified as a novel, water-soluble prodrug of the clinical candidate 2 suitable for intravenous administration in humans.
Asunto(s)
Acetales/síntesis química , Acetales/metabolismo , Antiinflamatorios no Esteroideos/síntesis química , Antieméticos/síntesis química , Morfolinas/síntesis química , Morfolinas/metabolismo , Antagonistas del Receptor de Neuroquinina-1 , Profármacos/síntesis química , Acetales/química , Acetales/farmacología , Animales , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/metabolismo , Antiinflamatorios no Esteroideos/farmacología , Antieméticos/química , Antieméticos/metabolismo , Antieméticos/farmacología , Antineoplásicos , Aprepitant , Cisplatino , Perros , Evaluación Preclínica de Medicamentos , Hurones , Cobayas , Humanos , Morfolinas/química , Morfolinas/farmacología , Profármacos/química , Profármacos/metabolismo , Profármacos/farmacología , Ratas , Solubilidad , Estereoisomerismo , Relación Estructura-Actividad , Vómitos/inducido químicamente , Vómitos/tratamiento farmacológico , AguaRESUMEN
To obtain gastroprokinetic agents with more potent and selective activity than metoclopramide and cisapride, a series of N-(4-benzyl-2-morpholinylmethyl)benzamides were designed and prepared. Their synthesis and structure-activity relationships were described. As a result, mosapride was selected as a promising candidate for potent gastroprokinetic activity with selective 5-HT4 receptor agonistic activity. As an extension to this project, the novel benzamide and the carboxamide derivatives having 1-benzyl-4-methylhexahydro-1,4-diazepine ring in the amine moiety were prepared and evaluated for 5-HT3 receptor antagonistic activity. DAT-582 was identified as an antiemetic agent in cancer chemotherapy. The asymmetric synthesis of DAT-582 and the SAR studies were briefly reviewed. In further modifications of the N-(1-benzyl-4-methylhexahydro-1,4-diazepin-6-yl)benzamides, the novel nicotinamides with 1-ethyl-4-methylhexahydro-1,4-diazepin ring were found to have potent 5-HT3 and dopamine D2 and D3 receptor antagonistic activities and to show weak central nervous system depression and extrapyramidal syndrome. After extensive SARs, AS-8112 was selected as a broad antiemetic agent.
Asunto(s)
Antieméticos/metabolismo , Fármacos Gastrointestinales/metabolismo , Receptores de Serotonina/metabolismo , Animales , Antieméticos/síntesis química , Antieméticos/farmacología , Diseño de Fármacos , Fármacos Gastrointestinales/síntesis química , Fármacos Gastrointestinales/farmacología , Estructura Molecular , Antagonistas de la Serotonina/síntesis química , Antagonistas de la Serotonina/metabolismo , Antagonistas de la Serotonina/farmacología , Relación Estructura-ActividadRESUMEN
New 6-chloro-2,3-dihydro-4(1H)-quinazolinones (24-27) have been synthesized and evaluated for gastrointestinal prokinetic and antiemetic activities in comparison with structurally related benzamides (21-22) and 6-chloro-2,3-dihydro-(1H)-1,3-benzoxazolin-4-ones (28). Their key pharmacophoric element has been defined as a 6-membered ring replacing the "virtual ring" arising from the hydrogen bond between amidic nitrogen and methoxy group in metoclopramide (1) and structurally related benzamides (2-10). Variations of heterocycle linking groups have pointed out that a lipophilic aromatic group in position 1 plays an important role for pharmacological properties, while the steric restriction and the modification of the side-chain nucleophilicity are uneffective both for the in vitro and in vivo activity. Some of these compounds very effectively enhance gut peristaltic activity in vitro (rabbit jejunum), increase gastric emptying of a semisolid meal (in rats), and inhibit cisplatin-induced emesis (in pigeons), favourably comparing with cisapride.
Asunto(s)
Antieméticos/síntesis química , Motilidad Gastrointestinal/efectos de los fármacos , Quinazolinas/síntesis química , Animales , Antieméticos/farmacología , Antieméticos/toxicidad , Fenómenos Químicos , Química Física , Cisplatino/antagonistas & inhibidores , Columbidae , Femenino , Vaciamiento Gástrico/efectos de los fármacos , Técnicas In Vitro , Yeyuno/efectos de los fármacos , Masculino , Ratones , Peristaltismo/efectos de los fármacos , Quinazolinas/farmacología , Quinazolinas/toxicidad , Conejos , Ratas , Ratas Wistar , Estimulación Química , Relación Estructura-ActividadRESUMEN
A series of 4-hydroxy-3-quinolinecarboxylic acid derivatives (6) and 4-hydroxy-2-oxo-1,2-dihydro-3-quinolinecarboxylic acid derivatives (7) were designed and synthesized as 5-HT3 receptor antagonists. Molecular modeling studies suggested that the 3-carbonyl moiety in 6 was almost coplanar to the plane of an aromatic ring, but in 7 there was a 30 degrees deviation. 4-Hydroxy substitution in quinoline derivatives enhanced affinity for the 5-HT3 receptors, and endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-4-hydroxy-3- quinolinecarboxamide (6f) exhibited the most potent activity in the Bezold-Jarisch (B-J) reflex test (ED50 = 0.1 micrograms/kg, iv) among quinoline derivatives 6. Although 4-hydroxy-2-oxo-1,2-dihydro-3-quinolinecarboxamide derivatives (7a) exhibited higher affinity (e.g., 7d: Ki = 0.48 nM) for the 5-HT3 receptors than ondansetron (Ki = 7.6 nM) or granisetron (Ki = 2.1 nM), these amides showed less potent activity in the B-J reflex test than the reference compounds. Interestingly, the ester derivatives 7c, 7f, and 7h eliminated affinity for the 5-HT3 receptors. These unusual structure-activity relationships and the deviation of the 3-carbonyl moiety from the plane of an aromatic ring suggest that the active conformation of 7a might be different from the proposed one for the preceding 5-HT3 antagonists. Thus, 6f was chosen for further studies. No receptor binding for a variety of ligands was significantly antagonized by 6f. Comparing the ratios of the ED50 value in the B-J reflex test (rat, iv) with the LD50 value in acute lethal toxicity (mouse, iv), 6f was proved to have a 600-fold wider margin of safety than ondansetron. Compound 6f dose-dependently attenuated both the incidence and frequency of emetic episodes induced by cisplatin in the dog (ED50 = 14 micrograms/kg, iv) more potently than ondansetron (ED50 = 210 micrograms/kg, iv). Compound 6f (KF-20170) is now under further investigation as a drug for treating gastrointestinal disorder.
Asunto(s)
Compuestos Bicíclicos Heterocíclicos con Puentes , Compuestos Bicíclicos con Puentes/síntesis química , Quinolinas/síntesis química , Antagonistas de la Serotonina , Animales , Antieméticos/síntesis química , Antieméticos/uso terapéutico , Compuestos Bicíclicos con Puentes/farmacología , Compuestos Bicíclicos con Puentes/uso terapéutico , Cisplatino , Perros , Cobayas , Frecuencia Cardíaca/efectos de los fármacos , Enlace de Hidrógeno , Espectroscopía de Resonancia Magnética , Masculino , Ratones , Modelos Moleculares , Estructura Molecular , Ondansetrón/farmacología , Quinolinas/farmacología , Quinolinas/uso terapéutico , Quipazina/metabolismo , Ratas , Ratas Wistar , Receptores de Serotonina/metabolismo , Serotonina/farmacología , Relación Estructura-Actividad , Vómitos/inducido químicamente , Vómitos/prevención & controlRESUMEN
Two new classes of potent 5-HT3 agents have been developed and examined as inhibitors of cytotoxic drug induced emesis in the ferret and dog. The absolute configuration of the most active molecules 10 and 18 have been determined by X-ray crystallography. These two compounds are more potent than known 5-HT3 receptor antagonists both in vivo and in vitro in blocking 5-HT3 receptor activation and preventing chemotherapeutic induced emesis. Compared with 5-HT3 antagonists, such as GR 38032F, zacopride, BRL 43694, and ICS 205-930, compound 10 was more potent in (1) inhibiting binding to 5-HT3 receptor binding sites in rat cortex (Ki = 0.17 nM), (2) blocking the von Bezold-Jarisch effect in the rat (lowest effective dose, 1 microgram/kg iv), and (3) inhibiting 5-HT-induced contraction of guinea pig ileum (lowest effective concentration, 10(-9) M). This novel agent was as effective given po as when given iv in reducing cisplatin-induced emetic episodes in the ferret (ED50 = 4 micrograms/kg iv or po). A 1 mg/kg po dose of 10 virtually abolished cisplatin-induced emesis for 10 h in the ferret. However, it was inactive against apomorphine or copper sulfate-induced vomiting. These data, coupled with receptor binding studies of ligands for D2-dopamine, a1, a2, 5-HT1, 5-HT2, and muscarinic receptors demonstrate that 10 is a highly selective 5-HT3 receptor antagonist with remarkable potency in vivo.
Asunto(s)
Amidas/síntesis química , Antieméticos/síntesis química , Benzamidas/síntesis química , Benzofuranos/síntesis química , Compuestos Bicíclicos Heterocíclicos con Puentes , Compuestos Bicíclicos con Puentes/síntesis química , Antagonistas de la Serotonina , Amidas/farmacología , Amidas/uso terapéutico , Animales , Antieméticos/farmacología , Antieméticos/uso terapéutico , Benzamidas/farmacología , Benzamidas/uso terapéutico , Benzofuranos/farmacología , Benzofuranos/uso terapéutico , Compuestos Bicíclicos con Puentes/farmacología , Compuestos Bicíclicos con Puentes/uso terapéutico , Corteza Cerebral/metabolismo , Cisplatino/toxicidad , Perros , Hurones , Cobayas , Íleon/efectos de los fármacos , Íleon/fisiología , Estructura Molecular , Contracción Muscular/efectos de los fármacos , Ratas , Serotonina/farmacología , Antagonistas de la Serotonina/farmacología , Relación Estructura-Actividad , Vómitos/inducido químicamente , Vómitos/prevención & control , Difracción de Rayos XRESUMEN
This report describes the development of novel benzamides which are orally active, highly potent, specific antagonists of 5-HT3 receptors. Described in this first report are the structure-activity relationships that led to novel structures with improved potency and selectivity. From this series of compounds, (S)-28 was identified and selected for further evaluation as a 5-HT3 receptor antagonist. Compared with 5-HT3 antagonists such as GR 38032F, BRL 43694, and metoclopramide, (S)-28 was most active in (a) inhibiting binding to 5-HT3 receptor binding sites in rat entorhinal cortex with an Ki value of 0.19 nM and (b) blocking cisplatin-induced emesis in the ferret with an ED50 value determined to be 9 micrograms/kg po.
Asunto(s)
Antieméticos/síntesis química , Benzamidas/síntesis química , Benzofuranos/síntesis química , Compuestos Bicíclicos Heterocíclicos con Puentes , Compuestos Bicíclicos con Puentes/síntesis química , Antagonistas de la Serotonina , Animales , Antieméticos/farmacología , Antieméticos/uso terapéutico , Benzamidas/farmacología , Benzamidas/uso terapéutico , Benzofuranos/farmacología , Benzofuranos/uso terapéutico , Unión Competitiva , Compuestos Bicíclicos con Puentes/farmacología , Compuestos Bicíclicos con Puentes/uso terapéutico , Corteza Cerebral/metabolismo , Cisplatino/toxicidad , Hurones , Granisetrón , Imidazoles/metabolismo , Imidazoles/farmacología , Imidazoles/uso terapéutico , Indazoles/farmacología , Indazoles/uso terapéutico , Indoles/metabolismo , Masculino , Metoclopramida/farmacología , Metoclopramida/uso terapéutico , Estructura Molecular , Ondansetrón , Ratas , Receptores de Serotonina/metabolismo , Relación Estructura-Actividad , Vómitos/inducido químicamente , Vómitos/prevención & controlRESUMEN
Metoclopramide (1) is a gastric motility stimulant and a weak dopamine and 5-HT3 receptor antagonist. Conformational restriction of the (diethylamino)ethyl side chain of 1 in the form of the azabicyclic tropane gave 3, a very potent gastric motility stimulant and 5-HT3 receptor antagonist but devoid of significant dopamine receptor antagonist properties. Subsequent alteration of the aromatic nucleus led to the identification of indazoles 6a-h, and 1- and 3-indolizines 7b-d and 8, and imidazo[1,5-alpha]pyridines 9 and 10, as potent 5-HT3 receptor antagonists devoid of either dopamine antagonist or gastric motility stimulatory properties. Further conformational restriction of the side chain identified quinuclidine 11 and isoquinuclidine 12 as potent 5-HT3 receptor antagonists which mimic the distorted chair conformation of the tropane with, in the case of 11, the N-methyl group axial. From these series, 6g (BRL 43694) was found to be both potent and selective and has been shown to be a very effective antiemetic agent against cytotoxic drug induced emesis both in the ferret and in man.